Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 5/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 3/20 | 0.39 |
| ▸ | CLK2 | P49760 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107173 | 0.81 | FLT3 (0.46) | RETFLT3LRRK2PRKD3MAP4K4 | |
| SCHEMBL8112985 | 0.76 | CCNT1 (0.48) | FLT3LRRK2PRKD3MAP4K4NTRK1 | |
| SCHEMBL20163122 | 0.75 | LRRK2 (0.35) | FLT3LRRK2PRKD3MAP4K4NTRK1 | |
| SCHEMBL4352960 | 0.75 | LRRK2 (0.58) | RETFLT3LRRK2PRKD3MAP4K4 | |
| SCHEMBL8107167 | 0.75 | FLT3 (0.46) | RETFLT3LRRK2PRKD3MAP4K4 | |
| SCHEMBL20640210 | 0.75 | CFTR (0.36) | RETLRRK2DYRK3LCKAURKB | |
| SCHEMBL24710755 | 0.74 | LRRK2 (0.51) | RETFLT3LRRK2PRKD3MAP4K4 | |
| SCHEMBL7021288 | 0.74 | LRRK2 (0.63) | RETFLT3LRRK2PRKD3MAP4K4 | |
| SCHEMBL20162808 | 0.74 | LRRK2 (0.38) | FLT3LRRK2PRKD3MAP4K4NTRK1 | |
| SCHEMBL20162807 | 0.74 | LRRK2 (0.38) | FLT3LRRK2PRKD3MAP4K4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | claimed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | claimed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | claimed |
| CN-115850268-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2023-03-28 | — | — | CN | claimed |
| CN-110337294-B | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2022-11-01 | — | — | CN | claimed |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| CN-115850268-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2023-03-28 | — | — | CN | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | RET 916/4885FLT3 1892/4885LRRK2 1435/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | RET 916/4885FLT3 1892/4885LRRK2 1435/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | RET 2334/4885FLT3 4039/4885LRRK2 1269/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | RET 962/4885FLT3 1848/4885LRRK2 1373/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | RET 962/4885FLT3 1848/4885LRRK2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.